A prospective non-randomized study with 17 patients noticed a reduction in lean body mass reaching 2.0 kg (p = 0.005) at 6 months compared to baseline [67,79], although the FDA has not yet approved any leptin analogues for the treatment of non-monogenic obesity [56]. Here, LEP is linked to obesity due to melanocortin 4 receptor deficiency.